Immutep Limited ADR (IMMP)
NASDAQ: IMMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.92M
- EPS (TTM)
- -$7.30
- Dividend yield
- None
- 52-week range
- 2.66 – 70.60
- Day range
- 3.09 – 3.41
- Volume / Avg
- 44.77K / 26.07K
- Beta
- —
- Shares outstanding
- 7.37M
52-week range
IMMP stock today
Shares of Immutep (IMMP) finished lower on Nov 20 at $3.11, a drop of 9.06% or $0.31 per share, versus the S&P 500's 3.70% decline. Shares are 95.6% below their 52-week high of $70.60 and 16.9% above the 52-week low of $2.66, near the bottom of the past year's range. IMMP is up 8.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 80.8%.
Immutep has posted a net loss over the last twelve months (EPS of -$7.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immutep
Company profileImmutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marc Voigt
- Headquarters
- Sydney, NSW
- Website
- immutep.com
Analyst forecast
ForecastConsensus
none
Avg. price target
$30.00+864.63%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
IMMP news
All IMMP news- Immutep Limited Reports 81.1% 12-month Disease-Free Survival in EFTISARC-NEO Phase II TrialNasdaq
- Immutep Posts New Survival Data From Phase 2 EFTISARC-NEO Trial;Stock UpNasdaqIMMP, BRK.A
- Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue SarcomaGlobeNewswire
- Immutep Further Expands United States Patent Estate for Efti-Based Combination TherapiesGlobeNewswire
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEOGlobeNewswire
- Immutep Limited - Depositary Receipt Price Target Increased by 19.55% to $80.11Nasdaq
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesGlobeNewswire
- Immutep Limited Receives A$2.16 million French R&D Tax IncentiveNasdaqIMMP, BF.B
Immutep peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RMTIRockwell Medical Inc. | 5.82 | -7.03% | $23.12M | vs IMMP |
| IXHLIncannex Healthcare Inc. | 1.86 | +6.90% | $23.34M | vs IMMP |
| ABVCABVC BioPharma Inc. | 0.8663 | -1.56% | $23.37M | vs IMMP |
| SCYXSCYNEXIS Inc. | 2.38 | -8.64% | $23.69M | vs IMMP |
| CRVOCervoMed Inc. | 1.46 | +9.77% | $22.09M | vs IMMP |
| LITSLite Strategy Inc. | 0.8026 | -4.03% | $23.99M | vs IMMP |
| AARDAardvark Therapeutics Inc. | 0.9226 | -7.74% | $20.20M | vs IMMP |
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs IMMP |
Indexes, lists and sector
Immutep stock FAQ
What is Immutep's stock price today?
IMMP last traded at $3.11 as of Nov 20, 4:00 PM EST, down 9.06% on the day. Prices are delayed at least 15 minutes.
Does Immutep pay a dividend?
No. Immutep does not currently pay a regular cash dividend.
Who is Immutep's CEO?
Mr. Marc Voigt is the chief executive officer of Immutep Limited ADR.
Has IMMP ever split its stock?
Yes. The most recent IMMP stock split was a 1-for-20 split on Sep 28, 2026, one of 2 splits on record.
What is the IMMP 52-week high?
The 52-week high for IMMP is $70.60 and the 52-week low is $2.66. The stock is currently 95.6% below its high.